Myriad Genetics MYGN reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM.
Here's what investors need to know about the announcement.
Earnings
Myriad Genetics missed estimated earnings by 216.67%, reporting an EPS of $-0.19 versus an estimate of $-0.06.
Revenue was down $10.90 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.03 which was followed by a 0.22% increase in the share price the next day.
Here's a look at Myriad Genetics's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | 0.01 | -0.07 | -0.02 | -0.02 |
EPS Actual | 0.04 | -0.03 | -0.02 | -0.02 |
Revenue Estimate | 171.00M | 156.62M | 163.40M | 165.04M |
Revenue Actual | 179.30M | 164.90M | 160.80M | 167.30M |
To track all earnings releases for Myriad Genetics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.